Clinical trials: Control Subjects
Hypertension
Dose Ranging, Safety and Tolerability of TOPROL-XL® Extended-Release Tablets in Hypertensive Pediatric Subjects
This was a 4-week, multicenter, double-blind, placebo-controlled, randomized, parallel-group study to determine the antihypertensive dose range, efficacy, safety and tolerability of TOPROL-XL ® (metoprolol succinate)…
- Trial name
- 307A (NCT00255528)
- Testing
- metoprolol succinate
- Where
- 31 sites in United States, Dominican Republic
- Volunteers
- 144 people
- Sponsor
- AstraZeneca
Asthma
Study Of Asthma In Patients Of African Descent
This study will last up to 62 weeks. You will visit the clinic up to 17 times. Certain clinic visits will include physical examination, medical history review and lung function tests.
- Trial name
- NCT00102765
- Testing
- fluticasone propionate/salmeterol powder, fluticasone propionate powder
- Where
- 75 sites in United States
- Volunteers
- 479 people
- Sponsor
- GlaxoSmithKline
Acne Vulgaris
A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris
UHE-101 cream, 1% ("UHE-101") is being developed for the topical treatment of acne vulgaris. The purpose of this study is to compare the safety and efficacy of twice daily topical application of UHE-101 cream for 12 weeks to its…
- Trial name
- NCT03307577
- Testing
- UHE-101 Cream, Vehicle Cream
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Therapeutics, Inc.
Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
The primary objectives of the study are to evaluate the efficacy of UX007 compared to placebo as measured by the reduction from randomization to Week 8 in frequency of seizures and to evaluate the safety of UX007 via adverse…
- Trial name
- NCT01993186
- Testing
- UX007
- Where
- 14 sites in United States, Australia and 5 more
- Volunteers
- 36 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Cystic Fibrosis
Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease
The purpose of this study is to assess the safety and effectiveness of multiple dosages of INS37217 compared to placebo over 28 days in subjects with mild to moderate cystic fibrosis (CF) lung disease.
- Trial name
- NCT00056147
- Testing
- denufosol tetrasodium (INS37217)
- Volunteers
- 90 people
- Sponsor
- Merck Sharp & Dohme LLC
Tinea Cruris, Jock Itch
Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Cruris
A research study to compare the safety and effectiveness of an investigational medication called NAFT-500 to placebo (no active treatment), when used in subjects with tinea cruris, also known as jock itch.
- Trial name
- NCT00750152
- Testing
- NAFT-500
- Where
- 20 sites in United States, Puerto Rico
- Volunteers
- 334 people, healthy volunteers welcome
- Sponsor
- Merz North America, Inc.
Allergic Rhinitis, Perennial Allergic Rhinitis
A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older
This is a 6-month multi-center, randomized, double-blind, placebo-controlled, parallel group, efficacy and safety study of ciclesonide HFA nasal aerosol administered once-daily to male and female subjects 12 years or older…
- Trial name
- NCT00953147
- Testing
- Ciclesonide HFA 80 mcg, Ciclesonide HFA 160 mcg
- Where
- 45 sites in United States
- Volunteers
- 1,110 people
- Sponsor
- Sumitomo Pharma America, Inc.
Sickle Cell Disease, Vaso-occlusive Crisis
Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis
GMI-1070 is a new drug that may reduce the stickiness of cells in the blood. The purpose of this study is to evaluate whether GMI-1070 can reduce the time it takes for pain to go away in patients with vaso-occlusive crisis (also…
- Conditions
- Sickle Cell Disease, Vaso-occlusive Crisis, Pain Crisis
- Trial name
- NCT01119833
- Testing
- GMI-1070
- Where
- 22 sites in United States, Canada
- Volunteers
- 81 people
- Sponsor
- GlycoMimetics Incorporated
Crohn's Disease
Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305)
The purpose of this study is to evaluate the efficacy and safety of ontamalimab in inducing clinical remission and endoscopic response in participants with moderate to severe Crohn's Disease.
- Trial name
- CARMEN CD 305 (NCT03559517)
- Testing
- Ontamalimab
- Where
- 138 sites in United States, Australia and 14 more
- Volunteers
- 30 people
- Sponsor
- Shire
Hypotension
Dose-response Study of Sodium Nitroprusside in Children Requiring Controlled Hypotension in the Operating Room
Sodium nitroprusside (SNP) has been approved for control of blood pressure in adults, yet there are no controlled studies in children.
- Trial name
- NCT00135668
- Testing
- Nitroprusside
- Where
- United States
- Volunteers
- 211 people
- Sponsor
- The Emmes Company, LLC
Common Wart
A Phase2 of A-101 Topical Solution in Subjects With Common Warts
The primary objective of this study is to evaluate the effectiveness of A-101 compared to vehicle when applied to 1 common target wart on the trunk or extremities.
- Trial name
- NCT03210337
- Testing
- A-101 Topical Solution, A-101 Vehicle Solution
- Where
- 17 sites in United States
- Volunteers
- 157 people
- Sponsor
- Aclaris Therapeutics, Inc.
Acute Otitis Externa
Comparative Efficacy and Safety of Ciprofloxacin 0.3% and Dexamethasone 0.1% in Acute Otitis Externa
The purpose of the study is to demonstrate the clinical therapeutic non-inferiority of EXL CDOS to commercially available Ciprofloxacin 0.3% and Dexamethasone 0.1% Sterile Otic Suspension (Ciprodex®, Alcon) in the treatment of…
- Trial name
- NCT02216071
- Testing
- Ciprodex®, EXL CDOS (Ciprofloxacin 0.3% and Dexamethasone 0.1%) Sterile Otic Suspension
- Where
- 48 sites in United States, Puerto Rico
- Volunteers
- 499 people
- Sponsor
- Exela Pharma Sciences, LLC.
Healthy
New Infant Formula Trial in Healthy Term Subjects on Growth, Body Composition, Tolerance and Safety
This study is initiated to investigate the effect of a new infant formula in healthy term subjects on growth, body composition, tolerance and safety.
- Trial name
- Venus (NCT01609634)
- Testing
- Test Product, Control Product 1, Control Product 2
- Where
- 2 sites in Singapore
- Volunteers
- 541 people, healthy volunteers welcome
- Sponsor
- Danone Asia Pacific Holdings Pte, Ltd.
Attention-Deficit/Hyperactivity Disorder
Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate
This study will evaluate how long it takes for ADHD symptoms to improve in subjects who are judged by the Investigator to have had an inadequate response to methylphenidate therapy.
- Trial name
- NCT01106430
- Testing
- Lisdexamfetamine Dimesylate, Atomoxetine Hydrochloride
- Where
- 64 sites in United States, Belgium and 8 more
- Volunteers
- 267 people
- Sponsor
- Shire
Rhinitis, Allergic, Perennial
Multicenter, Double-blind, Randomized, Placebo-controlled Study of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Study P06332)
This is a multicenter, randomized, parallel design, double-blind study of mometasone furoate (MF) in pediatric subjects with perennial allergic rhinitis.
- Trial name
- NCT01135134
- Testing
- Mometasone furoate
- Volunteers
- 333 people
- Sponsor
- Organon and Co
Acne Vulgaris
Clinical Study to Evaluate Tolerability and Safety of ARK-E021 Foam and to Monitor Clinical Effect in Acne Vulgaris Patients
This is a multicenter, randomized, double-blind, placebo-controlled, 3-arm, parallel-group, ambulatory safety and efficacy study of ARK-E021 topical foam of 5% and 10% in subjects with mild to moderate acne vulgaris.
- Trial name
- NCT01494285
- Testing
- ARK-E021 5%, ARK-E021 10%
- Where
- 3 sites in Israel
- Volunteers
- 157 people
- Sponsor
- M. Arkin 1999 Ltd.
Epilepsy, Monotherapy
Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older
Compare safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR) as monotherapy in newly or recently newly diagnosed subjects with primary safety variables including spontaneous reports of Adverse Events (AEs)…
- Trial name
- NCT01465997
- Testing
- Lacosamide, Carbamazepine-Controlled Release (CBZ-CR)
- Where
- 150 sites in United States, Australia and 27 more
- Volunteers
- 551 people
- Sponsor
- UCB BIOSCIENCES GmbH
Peanut Allergy
Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-201 in Subjects Ages 16-35 With Peanut Allergy
This study is a two-part Phase 1b/2a First-in-Human (FIH) randomized, double-blind, placebo-controlled clinical trial to assess the safety, tolerability, pharmacodynamics, and efficacy of multiple ascending doses of CNP-201 in…
- Trial name
- NCT04950504
- Testing
- CNP-201
- Where
- 9 sites in United States
- Volunteers
- 9 people
- Sponsor
- COUR Pharmaceutical Development Company, Inc.
Diabetes, Diabetes Mellitus, Type 1
A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Malaysia
This study is conducted in Asia. The aim of this observational study is to evaluate current status of diabetes management, control, and complications in diabetic subjects in Asia.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- DiabCare Asia (NCT00877526)
- Testing
- No treatment given
- Where
- Malaysia
- Volunteers
- 1,670 people
- Sponsor
- Novo Nordisk A/S
Ulcerative Colitis (UC)
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
The purpose of this study is to evaluate safety and efficacy of risankizumab in participants with ulcerative colitis (UC) in participants who responded to induction treatment with risankizumab in a prior AbbVie study of…
- Trial name
- COMMAND (NCT03398135)
- Testing
- risankizumab
- Where
- 426 sites in United States, Argentina and 41 more
- Volunteers
- 1,242 people
- Sponsor
- AbbVie